INT94122

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2001
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 21
Total Number 22
Disease Relevance 15.81
Pain Relevance 8.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Mmp23) endoplasmic reticulum (Mmp23)
Anatomy Link Frequency
uterine 4
neutrophil 2
dorsal root 1
MDM 1
Stromal cells 1
Mmp23 (Mus musculus)
Pain Link Frequency Relevance Heat
metalloproteinase 377 100.00 Very High Very High Very High
Morphine 3 99.76 Very High Very High Very High
antagonist 6 99.72 Very High Very High Very High
Dismenorea 30 99.62 Very High Very High Very High
Inflammation 90 98.32 Very High Very High Very High
Sciatic nerve 44 98.04 Very High Very High Very High
chemokine 8 95.76 Very High Very High Very High
cytokine 62 95.32 Very High Very High Very High
Neuropathic pain 19 93.72 High High
opioid receptor 1 92.28 High High
Disease Link Frequency Relevance Heat
Apoptosis 59 99.96 Very High Very High Very High
Amyloid Plaque 36 99.64 Very High Very High Very High
Dysmenorrhea 30 99.62 Very High Very High Very High
Alzheimer's Dementia 96 99.32 Very High Very High Very High
Nervous System Injury 23 99.20 Very High Very High Very High
Dermatitis 1 99.16 Very High Very High Very High
Cancer 345 99.12 Very High Very High Very High
Necrosis 7 98.88 Very High Very High Very High
Targeted Disruption 37 98.40 Very High Very High Very High
INFLAMMATION 97 98.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A matrix metalloproteinase inhibitor, ONO-4817, retards the development of mammary tumor and the progression of uterine adenomyosis in mice.
Negative_regulation (inhibitor) of metalloproteinase in uterine associated with cancer, dismenorea and metalloproteinase
1) Confidence 0.37 Published 2002 Journal Anticancer Res. Section Title Doc Link 12553022 Disease Relevance 1.04 Pain Relevance 0.46
The inhibitory effects of a novel matrix metalloproteinase inhibitor, ONO-4817, on the development of mammary tumors and the progression of uterine adenomyosis were examined in SHN mice.
Negative_regulation (inhibitor) of metalloproteinase in uterine associated with cancer, dismenorea and metalloproteinase
2) Confidence 0.37 Published 2002 Journal Anticancer Res. Section Abstract Doc Link 12553022 Disease Relevance 0.83 Pain Relevance 0.26
The effect of an inhibitor of matrix metalloproteinase on the invasion activity was also examined.
Negative_regulation (inhibitor) of metalloproteinase
3) Confidence 0.32 Published 2001 Journal Am. J. Obstet. Gynecol. Section Body Doc Link 11744912 Disease Relevance 0.09 Pain Relevance 0
RESULTS: Stromal cells that were obtained from adenomyotic uteri markedly invaded the reconstituted basement membrane matrix and gelatin, and the matrix metalloproteinase inhibitor suppressed the invasion.
Negative_regulation (inhibitor) of metalloproteinase in Stromal cells
4) Confidence 0.27 Published 2001 Journal Am. J. Obstet. Gynecol. Section Body Doc Link 11744912 Disease Relevance 0.07 Pain Relevance 0
Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice.
Negative_regulation (inhibitor) of metalloproteinase in uterine associated with metalloproteinase and dismenorea
5) Confidence 0.17 Published 2001 Journal Exp. Biol. Med. (Maywood) Section Title Doc Link 11393170 Disease Relevance 0.47 Pain Relevance 0.57
The inhibitory effects of a novel, orally active matrix metalloproteinase (MMP) inhibitor, ONO-4817, on the development of uterine adenomyosis induced experimentally by pituitary grafting were examined in mice.
Spec (examined) Negative_regulation (effects) of metalloproteinase in uterine associated with dismenorea and metalloproteinase
6) Confidence 0.17 Published 2001 Journal Exp. Biol. Med. (Maywood) Section Abstract Doc Link 11393170 Disease Relevance 0.29 Pain Relevance 0.38
A platelet activating factor antagonist and a matrix metalloproteinase inhibitor, which also inhibits tumor necrosis factor alpha release, were administered to animals at the time of the MDM inoculation.
Negative_regulation (inhibitor) of metalloproteinase in MDM associated with necrosis, cancer, antagonist and metalloproteinase
7) Confidence 0.15 Published 2001 Journal J. Neuroimmunol. Section Abstract Doc Link 11240016 Disease Relevance 1.06 Pain Relevance 0.30
We conclude that, as morphine is able to decrease metalloproteinase activity via the NO/NOS system, it may have a place in the treatment of several sarcomas including fibrosarcoma.
Negative_regulation (decrease) of metalloproteinase associated with fibrosarcoma, sarcoma, metalloproteinase and morphine
8) Confidence 0.06 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16386243 Disease Relevance 0.79 Pain Relevance 0.73
Doxycycline besides its ability to disrupt TTR amyloid fibrils, is known to be a matrix metalloproteinase inhibitor, and can in this way contribute to lower inflammation generated by the extracellular deposits [17].
Negative_regulation (inhibitor) of metalloproteinase associated with inflammation, alzheimer's dementia and metalloproteinase
9) Confidence 0.04 Published 2010 Journal J Transl Med Section Body Doc Link PMC2922089 Disease Relevance 1.53 Pain Relevance 0.31
Although shedding occurred normally in COX-1-deficient murine platelets, shedding was completely blocked by a broad-range metalloproteinase inhibitor and, more importantly, in mouse platelets expressing an inactive form of ADAM17.
Negative_regulation (inhibitor) of metalloproteinase in platelets associated with metalloproteinase
10) Confidence 0.03 Published 2005 Journal J. Biol. Chem. Section Abstract Doc Link 16179345 Disease Relevance 0.20 Pain Relevance 0.46
Doxycycline shown as a TTR fibril disrupter in vitro [9], when tested in transgenic TTR V30M mice, was capable of disaggregating amyloid deposits with concomitant decrease of metalloproteinase 9 (MMP-9), tissue inhibitor of metalloproteinase (TIMP-1), serum amyloid P component (SAP) and neutrophil gelatinase-associated lipocalin NGAL [10,11].
Negative_regulation (decrease) of metalloproteinase in neutrophil associated with targeted disruption, alzheimer's dementia, metalloproteinase and amyloid plaque
11) Confidence 0.02 Published 2010 Journal J Transl Med Section Body Doc Link PMC2922089 Disease Relevance 1.48 Pain Relevance 0.24
Doxycycline shown as a TTR fibril disrupter in vitro [9], when tested in transgenic TTR V30M mice, was capable of disaggregating amyloid deposits with concomitant decrease of metalloproteinase 9 (MMP-9), tissue inhibitor of metalloproteinase (TIMP-1), serum amyloid P component (SAP) and neutrophil gelatinase-associated lipocalin NGAL [10,11].
Negative_regulation (inhibitor) of metalloproteinase in neutrophil associated with targeted disruption, alzheimer's dementia, metalloproteinase and amyloid plaque
12) Confidence 0.02 Published 2010 Journal J Transl Med Section Body Doc Link PMC2922089 Disease Relevance 1.38 Pain Relevance 0.24
Furthermore, metalloproteinase inhibition did not affect MAG down-regulation in the dorsal root following intrathecally administered LPA [32], which mimics the nerve injury in terms of induction of neuropathic pain and its underlying mechanisms [8].
Negative_regulation (inhibition) of metalloproteinase in dorsal root associated with nervous system injury, neuropathic pain and metalloproteinase
13) Confidence 0.02 Published 2010 Journal Mol Pain Section Body Doc Link PMC2989310 Disease Relevance 1.07 Pain Relevance 0.93
This finding opens possibilities for using metalloproteinase inhibitors in the treatment of allergic contact dermatitis and other inflammatory diseases.
Negative_regulation (inhibitors) of metalloproteinase associated with inflammation, metalloproteinase, dermatitis and disease
14) Confidence 0.02 Published 2002 Journal Int. Immunopharmacol. Section Abstract Doc Link 12013508 Disease Relevance 0.70 Pain Relevance 0.28
Relevant to the disc, tissue inhibitor of metalloproteinase-1 and ECM fragments, including those from collagen, merit further study of their anti-angiogenic potential.
Negative_regulation (inhibitor) of metalloproteinase associated with metalloproteinase
15) Confidence 0.02 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575610 Disease Relevance 0.14 Pain Relevance 0.05
Invasion was inhibited by tissue inhibitor of metalloproteinase, TIMP-2, and the broad spectrum synthetic MMP inhibitor, GM6001.
Negative_regulation (inhibitor) of metalloproteinase associated with metalloproteinase
16) Confidence 0.01 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1450297 Disease Relevance 0.39 Pain Relevance 0.61
Invasion was inhibited by tissue inhibitor of metalloproteinase, TIMP-2, and the broad spectrum synthetic MMP inhibitor, GM6001.
Negative_regulation (inhibitor) of metalloproteinase associated with metalloproteinase
17) Confidence 0.01 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1450297 Disease Relevance 0.39 Pain Relevance 0.59
In a model of TNF-induced cardiomyopathy through cardiac-specific TNFalpha expression, p50 KO mice had improved diastolic and systolic function, suppressed matrix metalloproteinase activity and expression, and improved survival in male mice [53].
Negative_regulation (suppressed) of metalloproteinase associated with cardiomyopathy and metalloproteinase
18) Confidence 0.01 Published 2010 Journal Heart Fail Rev Section Body Doc Link PMC3003782 Disease Relevance 0.52 Pain Relevance 0.20
TIMP: tissue inhibitor of metalloproteinase
Negative_regulation (inhibitor) of metalloproteinase associated with metalloproteinase
19) Confidence 0.01 Published 2005 Journal Respir Res Section Body Doc Link PMC548519 Disease Relevance 0.68 Pain Relevance 0.32
Furthermore, it has been previously demonstrated that metalloproteinase inhibitors enhances the biological activity of soluble TRAIL [27].
Negative_regulation (inhibitors) of metalloproteinase associated with metalloproteinase
20) Confidence 0.01 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.65 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox